Abstract:Imaging detection of interlinked dual proteases is imperative for precise tumor imaging, which remains challenging due to limited modification position of specific substrate and possible steric hindrance. Herein, we have developed a unimolecular chemiluminescent probe (LGP-CL) tandemly activated by two proteases interlinked with liver cancer to achieve precise tumor imaging. Probe LGP-CL consists of a phenoxy-dioxetane scaffold caged by a tripeptide substrate (LGP, leucine-glycine-proline) as the sensing layer, which can be cleaved sequentially by aminopeptidase N (APN) and dipeptidyl peptidase IV (DPPIV) to turn on a strong chemiluminescent signal, and silenced by specific inhibitor of each enzyme, which accounts for an integrated logic gate (AND, OR and INHIBIT). The successful cleavage of dual proteases on the metabolic site depends on the proper structure of the tripeptide substrate, as confirmed by two probes design. Probe LGP-CL (LGP as the substrate) enables the excellent “dual-lock-dual-key” fit with a 382-fold enhancement of chemiluminescent emission while no obvious signal is observed by using GPL-CL (GPL as the substrate). By virtue of its rapid response (several minutes), high sensitivity and good cell viability, probe LGP-CL has been utilized to evaluate upregulated levels of proteases in vitro and in living systems, especially to distinguish liver tumor cells (HepG2) from others (LO2, MCF-7, MCF-10a and RAW264.7). Overall, the newly developed CL probe may facilitate rapid investigation into the role played by proteases in liver diseases, enabling timely selection appropriate treatment. Therefore, our work not only sheds light on the rational design of optical probes for dual protease imaging, but provides a promising tool for clinical diagnosis and even drug discovery.

Dual-locked fluorescent probes for precise diagnosis and targeted treatment of tumors

Dual-Targeted Molecular Probes for Cancer Imaging

Dual-locked spectroscopic probes for sensing and therapy

A Tumor-Targeting and Polarity-Specific Near-Infrared Fluorescent Probe for Accurate Cancer Diagnosis in Vivo

Activatable fluorescent probes for real-time imaging-guided tumor therapy

Research Advances In Integrated Theranostic Probes For Tumor Fluorescence Visualization And Treatment

Recent advances in small-molecule fluorescent probes for diagnosis of cancer cells/tissues

Dual‐Locked Fluorescent Probes Activated by Aminopeptidase N and the Tumor Redox Environment for High‐Precision Imaging of Tumor Boundaries

Novel Dual-Function Near-Infrared II Fluorescence and PET Probe for Tumor Delineation and Image-Guided Surgery.

Recent Advances in the Enzyme-Activatable Organic Fluorescent Probes for Tumor Imaging and Therapy

A Novel Near-Infrared Theranostic Probe for Accurate Cancer Chemotherapy in Vivo by a Dual Activation Strategy

Biosynthetic molecular imaging probe for tumor-targeted dual-modal fluorescence/magnetic resonance imaging

A dual-protease-triggered chemiluminescent probe for precise tumor imaging

Oncogene-targeting Nanoprobes for Early Imaging Detection of Tumor

Color-Convertible, Unimolecular, Micelle-Based, Activatable Fluorescent Probe for Tumor-Specific Detection and Imaging in Vitro and in Vivo

An AND-gate Bioluminescent Probe for Precise Tumor Imaging

A “dual-key-and-lock” molecular probe for accurate diagnosis of melanoma

Recent Advances in Small-Molecule Fluorescent Probes with the Function of Targeting Cancer Receptors

Selectivity Comparison of Tumor-Imaging Probes Designed Based on Various Tumor-Targeting Strategies: A Proof of Concept Study

1,2‐Dioxetane‐based Chemiluminescence Probes for Tumor Optical Molecular Imaging

Application of Intelligent Response Fluorescent Probe in Breast Cancer